Conversion initiative gives ‘significant’ boost to Remicade biosimilar use

An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.
“In talking with patients, many of them had great questions about the data available to support continued safety and efficacy when switching from an originator product to a biosimilar,” Sarah Steedman, PharmD, CPP, of the University of North Carolina (UNC) Medical Center, in Chapel Hill, told Healio. “It was then that we realized that we,

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.